tirzepatide eli lilly - Search News

News

Eli Lilly, Mounjaro and Zepbound

Health News Florida · 2d

Eli Lilly sues companies selling alternative versions of its weight loss drug

The drug company Eli Lilly is suing four telehealth companies for allegedly selling copies made by compounding pharmacies of its drug Zepbound.

UPI on MSN · 3d

Eli Lilly sues telehealth companies for selling Mounjaro, Zepbound compounds

Eli Lilly Wednesday filed lawsuits against four telehealth companies alleging they are deceiving consumers by selling compounds of slightly-different versions of Lilly drugs.

Eli Lilly Files Slew of Lawsuits Over Zepbound and Mounjaro

Eli Lilly alleges Willow falsely claims its products are safe, effective and superior to its FDA-approved tirzepatide medicines, sold under Lilly's brand names: Mounjaro, which treats diabetes, and Zepbound, which treats obesity.

Pharmaceutical Technology on MSN2d

Eli Lilly sues Mochi Health and others for ‘deceptive’ tirzepatide marketing

Mochi Health Corp, Fella Health and Delilah, Willow Health Services, and Henry Meds are the named companies in Eli Lilly’s ...

Fierce Pharma2d

Texas outsourcer in Lilly's compounded tirzepatide lawsuit hit with FDA warning letter

A Houston-based compounding pharmacy that was recently roped into Eli Lilly’s fight against knockoff GLP-1s has landed in the ...

Lilly Takes Four Compounders to Court for Allegedly Producing Knockoff Tirzepatide

In December 2024, the FDA affirmed that the shortage of tirzepatide, marketed as Zepbound for weight loss, had ended, ...

Houston Public Media2d

Eli Lilly sues Houston-based compounding pharmacy over alleged ‘knockoff’ obesity, diabetes drugs

Eli Lilly’s legal actions against Empower Pharmacy and other compounding pharmacies come several months after the FDA ...

2don MSN

Eli Lilly sues telehealth companies selling compounded Zepbound, Mounjaro

Eli Lilly is suing four telemedicine companies selling compounded versions of its blockbuster obesity drug Zepbound and its ...

1d

Analysts Maintain Buy Ratings on Eli Lilly Stock (LLY) as Q1 Earnings Loom

Eli Lilly (LLY) is scheduled to release its Q1 earnings on May 1, and analysts continue to stay positive, holding onto Buy ...

Eli Lilly Intensifies Legal Battle Over Tirzepatide Knockoff Sales

Eli Lilly escalates its crackdown on unauthorized tirzepatide copies, filing lawsuits against four compounders accused of ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results